Question 1.

A phase I study was conducted to test the safety of a new drug among healthy subjects. Because the new drug is primarily cleared kidney. renal clearance of a biomarker is used as an indicator of kidney function. The researchers compared the clearance of the biomarker between subjects who received the new drug and those receiving the placebo. The statistical results are presented in the Tables below. Treatment N Mean Std. Deviation Std. Error Mean Clearance Placebo 15 1.21 0.32 .03 New drug 15 1.49 0.45 .12 Levene's Test for Equalily ol' ttest for Means Variances 915% CI of the Difference Big. {2- Mean F Slg' l at tailed} Difference Lower Upper Eq ual variances 1.653 0.209 4.85? 28 0.0?4 0.2?533 4162553 0.0?595 assumed Eq ual variances 4.85? 23.956 0.0?6 O.2?533 41.62991 0.0?924 not assumed What alpha level was used for the statistical analysis? A phase I study was conducted to test the safety of a new drug among healthy subjects. Because the new drug is primarily cleared kidney, renal clearance of a biomarker is used as an indicator of kidney function. The researchers compared the clearance of the biomarker between subjects who received the new drug and those receiving the placebo. The statistical results are presented in the Tables below. Treatment N Mean Std. Deviation Std. Error Mean Clearance Placebo 15 1.21 0.32 08 New drug 15 1.49 0.48 .12 Levene's Test for Equality of t-test for Means 97.5% CI of the Difference Variances F Sig. (2- Mean Sig. t df Difference Lower tailed) Upper Equal variances 1.653 0.209 -1.857 28 0.074 -0.27533 -0.62653 0.07586 assumed Equal variances -1.857 23.956 0.076 -0.27533 -0.62991 0.07924 not assumed Based on the statistical analysis, what p-value to be reported from the study? O 0.025 O 0.05 O 0.209 O 0.074 O 0.076